查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1412263

胃輕癱藥物市場：按藥物類別、適應症、銷售管道分類 - 全球預測 2024-2030 年

Gastroparesis Drugs Market by Drug Class (Anti-Emetic Agents, Botulinum Toxin Injections, Prokinetic Agents), Indication (Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis), Sales Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年胃輕癱藥物市場規模為43.7億美元，2024年達45.4億美元，預計2030年將達到68.5億美元，複合年成長率為6.61%。

全球胃輕癱藥物市場

主要市場統計
基準年[2023] 43.7億美元
預測年份 [2024] 45.4億美元
預測年份 [2030] 68.5億美元
複合年成長率（%） 6.61%
胃輕癱治療藥物市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估胃輕癱藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對胃輕癱藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-胃輕癱治療藥物市場的市場規模與預測是多少？

2-胃輕癱藥物市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3-胃輕癱藥物市場的技術趨勢和法律規範是什麼？

4-胃輕癱藥物市場主要供應商的市場佔有率為何？

5-進入胃輕癱藥物市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地患有糖尿病的人數正在增加。
      • 增加對醫療基礎設施的投資，以改善獲得醫療服務的機會
    • 抑制因素
      • 降血脂藥物製劑所用原料價格昂貴。
    • 機會
      • 開發新藥的持續研究和開發活動
      • 全球監管機構核准的藥品數量增加
    • 任務
      • 服用胃輕癱治療藥物相關的嚴重副作用
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章依藥物類別分類的胃輕癱治療藥物市場

  • 止吐藥
  • 肉毒毒素注射
  • 運動促進者

第7章胃輕癱治療藥物市場（依適應症）

  • 糖尿病性胃輕癱
  • 特發性胃輕癱
  • 術後胃輕癱

第8章胃輕癱治療藥物市場：依銷售管道

  • 離線
    • 醫院藥房
    • 零售藥房
  • 線上的

第9章 北美及南美胃輕癱藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太胃輕癱藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東與非洲胃輕癱藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析

第13章競爭產品組合

  • 主要公司簡介
    • Abbott Laboratories
    • AbbVie Inc.
    • Amneal Pharmaceuticals, Inc.
    • ANI Pharmaceuticals, Inc.
    • AstraZeneca PLC
    • Atlantic Healthcare PLC
    • Bausch Health Companies Inc.
    • Bristol-Myers Squibb Company
    • Cadila Pharmaceuticals Limited
    • Cairn Diagnostics
    • Evoke Pharma, Inc.
    • GlaxoSmithKline PLC
    • Johnson & Johnson Services, Inc.
    • Kyowa Kirin International plc
    • Lupin Limited
    • Medtronic PLC
    • Neurogastrx, Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Processa Pharmaceuticals, Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Theravance Biopharma
    • Vanda Pharmaceuticals Inc.
    • Viatris Inc.
  • 主要產品系列

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-C002B1C99722

[199 Pages Report] The Gastroparesis Drugs Market size was estimated at USD 4.37 billion in 2023 and expected to reach USD 4.54 billion in 2024, at a CAGR 6.61% to reach USD 6.85 billion by 2030.

Global Gastroparesis Drugs Market

KEY MARKET STATISTICS
Base Year [2023] USD 4.37 billion
Estimated Year [2024] USD 4.54 billion
Forecast Year [2030] USD 6.85 billion
CAGR (%) 6.61%
Gastroparesis Drugs Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Gastroparesis Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Gastroparesis Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Gastroparesis Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amneal Pharmaceuticals, Inc., ANI Pharmaceuticals, Inc., AstraZeneca PLC, Atlantic Healthcare PLC, Bausch Health Companies Inc., Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Cairn Diagnostics, Evoke Pharma, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Kyowa Kirin International plc, Lupin Limited, Medtronic PLC, Neurogastrx, Inc., Novartis AG, Pfizer, Inc., Processa Pharmaceuticals, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Theravance Biopharma, Vanda Pharmaceuticals Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Gastroparesis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Anti-Emetic Agents
    • Botulinum Toxin Injections
    • Prokinetic Agents
  • Indication
    • Diabetic Gastroparesis
    • Idiopathic Gastroparesis
    • Post-surgical Gastroparesis
  • Sales Channel
    • Offline
      • Hospitals Pharmacies
      • Retail Pharmacies
    • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Gastroparesis Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Gastroparesis Drugs Market?

3. What are the technology trends and regulatory frameworks in the Gastroparesis Drugs Market?

4. What is the market share of the leading vendors in the Gastroparesis Drugs Market?

5. Which modes and strategic moves are suitable for entering the Gastroparesis Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Gastroparesis Drugs Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in diabetic population across the globe
      • 5.1.1.2. Rising investment in healthcare infrastructure to enhance healthcare accessibility
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of raw materials used in formulation of hyperlipidemia drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Continuous research & development activities for new drug development
      • 5.1.3.2. Increasing drug approvals by the regulatory authorities worldwide
    • 5.1.4. Challenges
      • 5.1.4.1. Severe side effects associated with the consumption of gastroparesis drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Gastroparesis Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-Emetic Agents
  • 6.3. Botulinum Toxin Injections
  • 6.4. Prokinetic Agents

7. Gastroparesis Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Diabetic Gastroparesis
  • 7.3. Idiopathic Gastroparesis
  • 7.4. Post-surgical Gastroparesis

8. Gastroparesis Drugs Market, by Sales Channel

  • 8.1. Introduction
  • 8.2. Offline
    • 8.3.1. Hospitals Pharmacies
    • 8.3.2. Retail Pharmacies
  • 8.3. Online

9. Americas Gastroparesis Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Gastroparesis Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Gastroparesis Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. AbbVie Inc.
    • 13.1.3. Amneal Pharmaceuticals, Inc.
    • 13.1.4. ANI Pharmaceuticals, Inc.
    • 13.1.5. AstraZeneca PLC
    • 13.1.6. Atlantic Healthcare PLC
    • 13.1.7. Bausch Health Companies Inc.
    • 13.1.8. Bristol-Myers Squibb Company
    • 13.1.9. Cadila Pharmaceuticals Limited
    • 13.1.10. Cairn Diagnostics
    • 13.1.11. Evoke Pharma, Inc.
    • 13.1.12. GlaxoSmithKline PLC
    • 13.1.13. Johnson & Johnson Services, Inc.
    • 13.1.14. Kyowa Kirin International plc
    • 13.1.15. Lupin Limited
    • 13.1.16. Medtronic PLC
    • 13.1.17. Neurogastrx, Inc.
    • 13.1.18. Novartis AG
    • 13.1.19. Pfizer, Inc.
    • 13.1.20. Processa Pharmaceuticals, Inc.
    • 13.1.21. Sanofi S.A.
    • 13.1.22. Takeda Pharmaceutical Company Limited
    • 13.1.23. Theravance Biopharma
    • 13.1.24. Vanda Pharmaceuticals Inc.
    • 13.1.25. Viatris Inc.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. GASTROPARESIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GASTROPARESIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GASTROPARESIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GASTROPARESIS DRUGS MARKET DYNAMICS
  • FIGURE 7. GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 8. GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. GASTROPARESIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GASTROPARESIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 6. GASTROPARESIS DRUGS MARKET SIZE, BY ANTI-EMETIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GASTROPARESIS DRUGS MARKET SIZE, BY BOTULINUM TOXIN INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. GASTROPARESIS DRUGS MARKET SIZE, BY PROKINETIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 10. GASTROPARESIS DRUGS MARKET SIZE, BY DIABETIC GASTROPARESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GASTROPARESIS DRUGS MARKET SIZE, BY IDIOPATHIC GASTROPARESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GASTROPARESIS DRUGS MARKET SIZE, BY POST-SURGICAL GASTROPARESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 14. GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 16. GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 66. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 86. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 90. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 94. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 107. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 111. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 115. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 119. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 123. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 127. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 131. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 135. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 139. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 143. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 147. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 151. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 155. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 163. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 167. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 171. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 175. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 187. GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 188. GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. GASTROPARESIS DRUGS MARKET LICENSE & PRICING